Yves J. Ribeill, Ph.D, President and Chief Executive Officer of Scynexis, Inc. (SCYX), announced that its SCY-078 is in Phase II at Canaccord Genuity’s 34th Annual Growth Conference at the Intercontinental Hotel in Boston, Massachusetts.
Scynexis is a pharmaceutical company aimed at the development and commercialization of anti-infectives to address significant unmet therapeutic needs. Its lead product candidate, SCY-078, is an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. The company also is targeting the animal health market.
FOR THE LATEST TWST BIOTECHNOLOGY REPORT, CLICK HERE.
Ribeill said there is “significant unmet need” in the invasive fungal infection sector, which he said was a $3.6 billion worldwide market. The company is targeting such diseases as dry eye in humans and animals. “For the moment, we’re focused on the anti-fungal compound.” There are high mortality rates for invasive funguses like candidiasis-IC and invasive aspergillosis. Immune-suppressed people are particularly vulnerable to them.
Scynexis also has revenue-generating opportunities outside its non-core assets, with R&D platforms providing partnership opportunities, Ribeill said. Scynexis has a Cyclophilin inhibitor platform and an established animal drug discovery service, he said.
FOR THE FULL PRESENTATION, CLICK HERE.
Matt Flake, President and CEO of Q2 Holdings Inc (QTWO), Presents at Canaccord Genuity Global Growth Conference
August 15, 2014
Francois Nader, President and CEO of NPS Pharmaceuticals, Inc. (NPSP), Presents at Canaccord Genuity Growth Conference
August 19, 2014
Dr. Daniel Gold, President and CEO of MEI Pharma Inc (MEIP), Presents at Canaccord Genuity Growth Conference
August 19, 2014
Sanj K. Patel, President and CEO of Synageva BioPharma Corp. (GEVA), Presents at the Canaccord Genuity Growth
August 15, 2014
Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals (JAZZ), Presents at Canaccord Genuity Growth Conference
August 15, 2014
